News

Cell Therapeutics has reported that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as

Merck KGaA announced that its US affiliate received a refuse to file letter from the FDA on the New Drug Application (NDA) for Cladribine tablets, Merck Serono’s proprietary

Novavax has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age

Caire, which operates under Chart’s BioMedical segment, has completed the previously announced acquisition of Covidien’s oxygen therapy business, including the design, manufacturing, and sales and service functions worldwide.

Bayer Schering Pharma (Bayer Schering) has reported the enrollment of first patient in an international clinical Phase III trial to evaluate the efficacy and safety of Florbetaben (BAY

Xencor has licensed its XmAb and Xtend technology platforms to Centocor Research & Development (Centocor) for the optimisation of Centocor’s antibody drug candidates. The license follows a 2009

QRxPharma has initiated registration in the pivotal (Study 008) Phase 3 study of MoxDuoIR for moderate to severe acute pain. The company expects to complete dosing by close

GlaxoSmithKline (GSK) has filed its vaccine for the prevention of rotavirus gastroenteritis (approved as Rotarix in a number of countries outside of Japan). The company claims that the

Dishman Netherlands has oppened its containment cGMP laboratory on November 27, 2009. It was inaugrated by Jay Vyas, chairman and owner of the Indian Dishman Group. Important attendees